Want to see ACET full AI Analyst Report?
ACET Stock Chart & Stats
$7.79
-$0.63(-7.48%)
At close: 4:00 PM EDT
$7.79
-$0.63(-7.48%)
Day’s Range― - ―
52-Week Range$6.01 - $17.43
Previous Close$7.79
Volume71.21K
Average Volume (3M)90.40K
Market Cap
$84.70M
Enterprise Value-$50.52
Total Cash (Recent Filing)$137.59M
Total Debt (Recent Filing)$13.90M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Aug 06, 2026EPS Estimate
-1.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.90
Shares Outstanding9,348,236
10 Day Avg. Volume97,107
30 Day Avg. Volume90,404
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$20.50Price Target Upside163.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low absolute debt load and debt-to-equity around 0.10 materially reduce insolvency risk and preserve financial optionality for a clinical-stage biotech. This balance sheet flexibility supports continued R&D spending or strategic partnerships without crippling interest burdens.
Scalable Off-the-shelf Γδ T‑cell ModelA focus on allogeneic, off-the-shelf γδ T cells targets a structural industry trend toward scalable cell therapies. If clinically validated, this model enables batch manufacturing, faster patient access and lower per-dose costs versus autologous approaches, supporting durable commercial scalability.
Governance Continuity And OversightRe-election of directors and auditor ratification provide continuity in strategic oversight and financial reporting governance. Stable board composition and an established auditor reduce execution and disclosure risk during lengthy clinical development cycles, aiding predictable stewardship.
Bears Say
No Revenue, Large Net LossesThe company remains pre-revenue and loss-making at scale, meaning operating performance cannot self-fund R&D or trials. Persistent large losses lengthen the path to sustainability and make future operations conditional on successful clinical outcomes and external capital.
Severe Cash Burn And Weak Cash GenerationNegative operating and free cash flow of roughly $90M annually indicates the business is consuming cash at pace and that losses translate directly into cash outflows. This structural cash burn increases refinancing frequency and dilution risk unless clinical progress materially reduces spend or attracts partners.
Eroding Equity Base; Reliance On External FundingA declining equity base reflects cumulative dilution and losses, signalling repeated dependence on capital markets. Continued erosion undermines shareholder buffer and raises the probability of future equity raises, which can dilute existing holders and constrain long-term financial stability.
Adicet Bio News
ACET FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest stock price was $6.01 and its highest was $17.43 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $84.70M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on May 13, 2026. The company reported -$1.88 earnings per share for the quarter, beating the consensus estimate of -$3.076 by $1.196.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -1.69.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,348,236 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.88 in its last earnings report, beating expectations of -$3.076. Following the earnings report the stock price went up 4.213%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.50 (163.16% Upside)
$20.50 (163.16% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 77.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.44%
Trailing 12-Months
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$20.50
▲(163.16% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
22.02% Insiders
9.74% Mutual Funds
44.52% Other Institutional Investors
19.56% Public Companies and
Individual Investors